Successful Polymyxin B Hemoperfusion Treatment Associated With Serial Reduction of Serum Anti-CADM-140/MDA5 Antibody Levels in Rapidly Progressive Interstitial Lung Disease With Amyopathic Dermatomyositis.

Bibliographic Details
Title:	Successful Polymyxin B Hemoperfusion Treatment Associated With Serial Reduction of Serum Anti-CADM-140/MDA5 Antibody Levels in Rapidly Progressive Interstitial Lung Disease With Amyopathic Dermatomyositis.
Authors:	Aoi Teruya¹ tanaka.aoil0003@gmail.com, Kodai Kawamura¹, Kazuya Ichikado¹, Shinji Sato², Yuko Yasuda¹, Masakazu Yoshioka¹
Source:	CHEST. Dec2013, Vol. 144 Issue 6, p1934-1936. 3p.
Subject Terms:	LUNG diseases, RESPIRATORY diseases, DERMATOMYOSITIS, ENZYME-linked immunosorbent assay, HEMOPERFUSION, IMMUNOGLOBULINS
Abstract:	The article discusses the medical case of a 52-year-old man with rapidly progressive interstitial lung disease (RP-ILD) with clinically amyopathic dermatomyositis (CADM). The case showed the usefulness of determining the anti-CADM-140/MDA45 antibody levels by enzyme-linked immunosorbent assay to monitor the disease activity in patients with RP-ILD. Plymyxin-B direct hemoperfusion (PMX-DHP) helped reduce the antibody concentration.
Database:	Academic Search Complete